Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Efficacy of Incobotulinumtoxin Type A (Xeomin®) in the Management of Sialorrhea in Neurodegenerative Diseases
Marvulli R*, Mastromauro L, De Venuto G, Napolitano M, Falcicchio M, Gallo GA, Schivardi E, Fiore P, Megna M and Ianieri GDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
- *Corresponding Author:
- Marvulli R
Department of Basic Sciences
Neuroscience and Sense Organs
University of Bari “Aldo Moro”
Bari, Italy
Tel: 393395238606
E-mail: ricmarv81@hotmail.it
Received date: June 22, 2017; Accepted date: July 24, 2017; Published date: July 31, 2017
Citation: Marvulli R, Mastromauro L, De Venuto G, Napolitano M, Falcicchio M, et al. (2017) Efficacy of Incobotulinumtoxin Type A (Xeomin®) in the Management of Sialorrhea in Neurodegenerative Diseases. J Alzheimers Dis Parkinsonism 7:356. doi:10.4172/2161-0460.1000356
Copyright: © 2017 Marvulli R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Introduction: One of the symptoms of two very common and serious neurodegenerative diseases such as Amyotrophic Lateral Sclerosis and Parkinson’s disease is sialorrhea. It can cause macerations and fissures in perioral region, halitosis, dysarthria, aspiration penumonia, asphyxiation and patient’s awkwardness. Management can be conservative (medical therapy using anticholinergic drugs) or more invasive (surgery with excision of salivary glands, duct’s ligation and transposition). Botulinum toxin A is a non invasive and poor side effects alternative. Aim of this study is to examine therapeutic resources for sialorrhea in Amyotrophic Lateral Sclerosis and Parkinson’s disease, by objective and subjective evaluation. Materials and methods: 20 patients with sialorrhea caused by Parkinson’s disease (10 patients) and ALS (10 patients). Incobotulinum toxin A (XEOMIN®, Merz Pharma), was injected under ultrasound guide in the submandibular and parotid glands. At t0 (pre-injection), t1 (30 days later), t2 (90 days later), t3 (120 days later), t4 (150 days later) and t5 (180 days later, only in PD group) we submitted Visual Analogue Scale (VAS) to estimated the level of salivation (1 was the best state and 10 the worst state), Gauze’s test to perform the weighed of the gauze after 1 minute and Sugar lump’s test to evaluate time necessary for melting. Results: In Parkinson’s and ALS group gauze’s test, sugar lump’s test and VAS improved until 6 months (PD group) and 5 months (ALS group), with p<0,05. Conclusion: This study concludes that therapeutic resource with Botulinum toxin A is an efficient treatment option for sialorrhea in patients with ALS and PD.
